

SUPPLEMENTARY INFORMATION: The Army Benefit Center—Civilian replaces the old way of doing business and is a major change for management, supervisors, employees, CPOC, and Civilian Personnel Advisory Center (CPAC) staff. The ABC-C services include information and assistance regarding the Federal Employee's Health Benefits (FEHB) Program, the Federal Employees' Group Life Insurance (FEGLI) Program, the Thrift Savings Plan (TSP) Program, Civil Service Retirement System (CSRS) and Federal Employees' Retirement System (FERS), and survivor benefits (death and dismemberment claims).

Luz D. Ortiz,
Army Federal Register Liaison Officer.
[FR Doc. 02-23851 Filed 9-19-02; 8:45 am]
BILLING CODE 3710-08-M

DEPARTMENT OF DEFENSE

Department of the Army

Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning Method for Detecting Clostridium Botulinum Neurotoxin Serotypes, A, B, E and F in a Sample

AGENCY: Department of the Army, DOD.
ACTION: Notice.

SUMMARY: In accordance with 37 CFR 404.6 and 404.7, announcement is made of the availability for licensing of U.S. Patent Application No. 09/952,078 entitled "Method for Detecting Clostridium Botulinum Neurotoxin Serotypes A, B, E and F in a Sample," filed September 14, 2001. Foreign rights (PCT/US01/28641) are also available. The United States Government, as represented by the Secretary of the Army has rights in this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619-6664, both at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: Sensitive and specific enzyme-linked immunosorbent assays which detect Clostridium botulinum neurotoxins serotypes A, B, E, and F in a sample are described. The assay is based upon

affinity-purified antibodies directed against the C-fragments of each toxin. These assays demonstrate sensitivity close to that of the mouse bioassay without the use of animals and in a much simpler format than other assays of similar sensitivity.

Luz D. Ortiz,
Army Federal Register Liaison Officer.
[FR Doc. 02-23853 Filed 9-19-02; 8:45 am]
BILLING CODE 3710-08-M

DEPARTMENT OF DEFENSE

Department of the Army

Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning Compositions for Treatment of Hemorrhaging With Activated Factor VIIa in Combination With Fibrinogen and Methods of Using Same

AGENCY: Department of the Army, DOD.
ACTION: Notice.

SUMMARY: In accordance with 37 CFR 404.6 and 404.7, announcement is made of the availability for licensing of U.S. Patent Application No. 09/756,907 entitled "Compositions for Treatment of Hemorrhaging with Activated Factor VIIa in Combination with Fibrinogen and Methods of Using Same," filed January 10, 2001. Foreign rights (PCT/US01/00725) are also available. The United States Government, as represented by the Secretary of the Army has rights in this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619-6664, both at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: The combination of recombinant factor VIIa and fibrinogen is effective in treatment for bleeding where direct pressure, tourniquets, indirect pressure, surgical ligation, bandaging, and transfusion of blood or plasma products are typically used. The combination of factor VIIa and fibrinogen is administered intravenously, either sequentially or simultaneously. The compositions may be safely circulated in the blood vessels to sites of injury. This is effective for

single or multiple external or internal wounds.

Luz D. Ortiz,
Army Federal Liaison Officer.
[FR Doc. 02-23852 Filed 9-19-02; 8:45 am]
BILLING CODE 3710-08-M

DEPARTMENT OF DEFENSE

Department of the Army

Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning Easy Access Dental Field Operating and Treatment System Having Over-the-Patient Delivery

AGENCY: Department of the Army, DoD.
ACTION: Notice.

SUMMARY: In accordance with 37 CFR 404.6 and 404.7, announcement is made of the availability for licensing of U.S. Patent Application No. 09/828,601 entitled "Easy Access Dental Field Operating and Treatment System Having Over-the-Patient Delivery," filed April 6, 2001. Foreign rights are also available (PCT/US02/01283). The United States Government, as represented by the Secretary of the Army, has rights in this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619-6664, both at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: Dental treatment systems are systems which facilitate the delivery of dental services to patients. The application relates, in general, to portable dental treatment systems.

Luz D. Ortiz,
Army Federal Register Liaison Officer.
[FR Doc. 02-23849 Filed 9-19-02; 8:45 am]
BILLING CODE 3710-08-M